ePrints

Histiocytic neoplasms: Going, going, but not quite gone

Lookup NU author(s): Professor Matthew CollinORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2023 British Society for Haematology and John Wiley & Sons Ltd. BRAF and MEK inhibitors have revolutionised the treatment of patients with high-risk histiocytic neoplasms but does a complete response mean that treatment can be withdrawn?. Commentary on: Reiner et al. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. Br J Haematol 2023 (Online ahead of print). doi: 10.1111/bjh.18964.

Publication metadata

Author(s): Collin M

Publication type: Note

Publication status: Published

Journal: British Journal of Haematology

Year: 2023

Pages: Epub ahead of print

Online publication date: 17/08/2023

Acceptance date: 22/07/2023

ISSN (print): 0007-1048

ISSN (electronic): 1365-2141

Publisher: John Wiley and Sons Inc.

URL: https://doi.org/10.1111/bjh.19014

DOI: 10.1111/bjh.19014

PubMed id: 37592718

Share